MRES (Institute of Biomedical Research) PB Ratio: 0.43 (As of Jun. 26, 2026)


What is Institute of Biomedical Research PB Ratio?

Institute of Biomedical Research MRES PB Ratio is 0.43 as of Jun. 26, 2026.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Institute of Biomedical Research's share price is $0.0013. Institute of Biomedical Research's Book Value per Share for the quarter that ended in Dec. 2010 was $0.00. Hence, Institute of Biomedical Research's PB Ratio of today is 0.43.

The historical rank and industry rank for Institute of Biomedical Research's PB Ratio or its related term are showing as below:

MRES's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.8
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio

Institute of Biomedical Research  (OTCPK:MRES) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Institute of Biomedical Research PB Ratio Related Terms

Institute of Biomedical Research PB Ratio Historical Data

* Premium members only.

The historical data trend for Institute of Biomedical Research's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Institute of Biomedical Research PB Ratio Chart

Institute of Biomedical Research Annual Data
Trend Dec03 Dec04 Mar06 Mar07 Mar08 Mar09 Mar10
PB Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Institute of Biomedical Research Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 100.00

MRES vs HSTC, NTRR, VITIF: PB Ratio Comparison

For the Biotechnology subindustry, Institute of Biomedical Research's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Institute of Biomedical Research PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Institute of Biomedical Research's PB Ratio distribution charts can be found below:

* The bar in red indicates where Institute of Biomedical Research's PB Ratio falls into.


Institute of Biomedical Research PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Institute of Biomedical Research's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2010)
=0.0013/0.003
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PB Ratio=Market Cap /(Total Stockholders Equity-Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 0.43 mean?
Institute of Biomedical Research (MRES) has a PB Ratio of 0.43 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Institute of Biomedical Research and its competitors.
Is Institute of Biomedical Research's PB Ratio too high?
Institute of Biomedical Research's current PB Ratio is 0.43. The Biotechnology industry median PB Ratio is 2.80. Institute of Biomedical Research's value of 0.43 is 84.6% below this industry median.
How does Institute of Biomedical Research's PB Ratio compare to HSTC and NTRR?
Institute of Biomedical Research's PB Ratio of 0.43 can be compared against companies in the Biotechnology industry. The industry median PB Ratio is 2.80. Institute of Biomedical Research's value of 0.43 is 84.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Institute of Biomedical Research's current PB Ratio of 0.43 is 84.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Institute of Biomedical Research and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Institute of Biomedical Research's current PB Ratio is 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Institute of Biomedical Research stock overvalued right now?
Institute of Biomedical Research (MRES) has a current PB Ratio of 0.43. The current PB Ratio is 0.43 and 84.6% below the Biotechnology industry median of 2.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Institute of Biomedical Research (MRES), the current PB Ratio is 0.43 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Institute of Biomedical Research Business Description

Address Dubai Science Park, 13th Floor, South Tower, Dubai, ARE, 416452
Institute of Biomedical Research Corp is a biomedical research and development company. The company is focused on alternative plant-based food and medicine and mental health therapeutic research. The company uses brand name M2Bio Sciences engaged in deploying artificial intelligence, science and medicine, clinical research, and emerging technologies.